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Abstract
There is a strong association between genetic polymorphisms and the acenocoumarol dos-
age requirements. Genotyping the polymorphisms involved in the pharmacokinetics and
pharmacodynamics of acenocoumarol before starting anticoagulant therapy would result in
a better quality of life and a more efficient use of healthcare resources. The objective of this
study is to develop a new algorithm that includes clinical and genetic variables to predict the
most appropriate acenocoumarol dosage for stable anticoagulation in a wide range of
patients. We recruited 685 patients from 2 Spanish hospitals and 1 primary healthcare cen-
ter. We randomly chose 80% of the patients (n = 556), considering an equitable distribution
of genotypes to form the generation cohort. The remaining 20% (n = 129) formed the valida-
tion cohort. Multiple linear regression was used to generate the algorithm using the aceno-
coumarol stable dosage as the dependent variable and the clinical and genotypic variables
as the independent variables. The variables included in the algorithm were age, weight,
amiodarone use, enzyme inducer status, international normalized ratio target range and the
presence of CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), VKORC1 (rs9923231) and
CYP4F2 (rs2108622). The coefficient of determination (R2) explained by the algorithm was
52.8% in the generation cohort and 64% in the validation cohort. The following R2 values
were evaluated by pathology: atrial fibrillation, 57.4%; valve replacement, 56.3%; and
venous thromboembolic disease, 51.5%. When the patients were classified into 3 dosage
groups according to the stable dosage (<11 mg/week, 11–21 mg/week, >21 mg/week), the
percentage of correctly classified patients was higher in the intermediate group, whereas
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differences between pharmacogenetic and clinical algorithms increased in the extreme dos-
age groups. Our algorithm could improve acenocoumarol dosage selection for patients who
will begin treatment with this drug, especially in extreme-dosage patients. The predictability
of the pharmacogenetic algorithm did not vary significantly between diseases.
Introduction
Despite the development of new oral anticoagulants, coumarins are still the most widely used
anticoagulants for treating and preventing thromboembolism. Warfarin is the most frequently
prescribed coumarin worldwide, although acenocoumarol and phenprocoumon are preferen-
tially used in some countries. Although these vitamin K antagonists are effective for preventing
cardioembolic stroke, myocardial infarction and venous thrombosis, they double the incidence
of hemorrhage, and this risk is particularly high during the first month of therapy [1]. Accurate
dosing of coumarin anticoagulants is challenging due to the wide interindividual and intraindi-
vidual variability in the dosage necessary to achieve stable anticoagulation.
In the last decade, the identification of genetic variants influencing the metabolism of cou-
marins led to the publication of numerous articles focused on the potential of pharmacogenetic
information to personalize therapy and to anticipate the best therapeutic dosage for patients
starting coumarin treatment. Thus, the use of dosing algorithms that include genetic and non-
genetic factors has been the most common strategy for predicting the most appropriate dosage
of antivitamin-K oral anticoagulants [2–7].
A wide variety of studies, including several genome-wide association studies (GWAS), have
identified the primary genetic variants that influence warfarin and acenocoumarol dosing [8–
14]. Patients with variant alleles of CYP2C9, the primary enzyme that metabolizes S-warfarin
and S-acenocoumarol, require reduced dosages compared with those having wild-type alleles.
Warfarin and acenocoumarol dosing variability is also attributable to genetic polymorphisms
in vitamin K 2,3 epoxide reductase complex 1 (VKORC1). In addition, a subsequent finding
revealed that CYP4F2 genetic variants were associated with a clinically relevant effect on warfa-
rin requirements in the Caucasian population [13].
To obtain personalized warfarin dosages, several models have been developed that include
these genetic variants and demographic and clinical factors for various patient populations.
These algorithms explain approximately 51–59% of the variation in warfarin doses [4,15–17].
Although warfarin and acenocoumarol are very similar, they differ in their pharmacokinetic
and pharmacodynamic characteristics and their genetic influence. Warfarin algorithms cannot
therefore be applied to acenocoumarol [18].
To date, a number of algorithms have also been published for acenocoumarol in diverse
populations. Verde et al. constructed an ‘‘acenocoumarol-dose genotype score” based on the
number of alleles associated with a higher acenocoumarol dosage taken by each participant for
each polymorphism [19]. Two algorithms have been published for Indian populations, which
include demographic, clinical and genetic variants, and have obtained coefficients of determi-
nations of 41% and 61.5%, respectively [20,21]. In addition, 3 other algorithms have been
developed for European populations. The first algorithm, designed for a mixed population, was
published by the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) study
group and includes CYP2C9 and VKORC1 polymorphisms and clinical variables (age, sex,
weight, height and amiodarone use). When applied to the EU-PACT cohort, this algorithm
explained 52.6% of the dosage variance, whereas the nongenotype algorithm explained 23.7%
[22]. Another algorithm was developed by our group (La Paz University Hospital, LPUH) for a
cohort of patients with Thromboembolic Venous Disease (TVD) and considers the influence
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of clinical variables (age, body mass index [BMI], amiodarone use and enzyme-inducer use)
and genetic variations of CYP2C9, VKORC1, CYP4F2 and APOE. For our entire cohort, this
algorithm predicted 56.8% of the dose variance, whereas the clinical factors explained only
19% of the variability [23]. The last algorithm was developed by Cerezo-Manchado et al. in a
large cohort of patients undergoing anticoagulation therapy (n = 973) and includes clinical fac-
tors (age and BMI) and genetic variants (VKORC1, CYP2C9 and CYP4F2 polymorphisms).
The algorithm explained 50% of the variance in the acenocoumarol dosage, whereas the clinical
algorithm explained 16% [24].
The published algorithms differ in the variables included and the variables’ weight and
show differences in the population and methods used to develop the predictive models. The
clinical variables included in the algorithms differ essentially in terms of the inclusion or not of
sex or in terms of using weight and height instead of BMI. In addition, a number of algorithms
take into account the use of amiodarone and enzyme-inducer drugs while others do not. In
terms of the genetic variants, all algorithms included CYP2C9 and VKORC1 polymorphisms.
CYP4F2 is taken into account in a number of algorithms, and APOE is used only by the LPUH
group.
LPUH algorithm [23] was developed for a well-defined prospective cohort of patients with
TVD [Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)], whereas the other algo-
rithms [22,24] have typically included patient cohorts with various anticoagulation indications
(valve replacement [VR], atrial fibrillation [AF] and TVD). The objective of this study is to
develop a new algorithm in a larger prospective cohort of patients that would be useful for a
wider range of patients.
Materials and Methods
Study design and patients
Written informed consent was obtained from all patients prior to their participation in the
study. Ethics approval for this study was obtained from both clinical research ethics commit-
tees: LPUH of Madrid and San Cecilio University Hospital (SCUH) of Granada, Spain. This
was an observational, cross-sectional study. Patients were recruited from the various clinical
departments of LPUH of Madrid and SCUH of Granada and a primary health care center
(PHCC) belonging to LPUH. Participants included 685 patients who were treated according to
the disease in the various departments of the 2 hospitals and the PHCC. Inclusion criteria
included acenocoumarol anticoagulation for AF or TVD with a target INR of 2–3, and VR or
other diseases (OD) requiring anticoagulation, with a target INR of 2.5–3.5. The participants
were taking a stable dosage of acenocoumarol, defined as a weekly dose variation of<20% in
the last 3 consecutive months and an INR within 2–3 (AF and TVD) and 2.5–3.5 (VR and OD)
for at least the last 3 consecutive months. Exclusion criteria included renal (estimated creati-
nine clearance30 mL/min) and hepatic (Child-Plough stage) impairment, thyroid dysfunc-
tion and cancer.
The INR was measured according to the technique used in each recruiting center; all centers
have quality certifications with external controls. In LPUH the analysis was performed using a
semiautomated Thrombotrack1 CoaguLometer (Baxter) with Thrombotest reagents. SCUH
used the microINR from iLine microsystems, and PHCC used a portable INRatio (Grifols)
coagulometer.
Data collection and genotyping
The collected data included age, sex, race, body weight and height, INR results, acenocoumarol
dose administered in the last 3 consecutive months, concomitant medications and target INR
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range. Blood samples were collected in tubes containing ethylenediaminetetraacetic acid
(LPUH) and samples of buccal mucosa cells (SCUH) and stored at -20°C. For DNA extraction,
the QuickGene DNA blood kit S (Fujifilm, Düsseldorf, Germany) was used in LPUH; the DNA
extraction procedure in SCUH was performed according to the method previously published
by Freeman et al. [25], with a number of modifications described by Gómez-Martín A. et al.
[26]. KASPar1 (KBiosciences, Hoddesdon, UK), and TaqMan1 (Applied Biosystems, Foster
City, USA) technologies were used for genotyping. The genotype frequencies were calculated
and the distributions tested for Hardy-Weinberg equilibrium.
We randomly chose 80% of the patients (n = 556), considering an equitable genotype distri-
bution (CYP2C9, VKORC1 and CYP4F2) to form the generation cohort. The remaining 20%
(n = 129) formed the validation cohort of the new algorithm.
Statistical analysis
The results for the categorical data were expressed in absolute terms; such as percentages and
the comparison between groups were performed using the chi-squared test. The continuous
variables were expressed as means and standard deviation (SD) and were compared using Stu-
dent´s t-test and ANOVA.
Univariate analyses were performed for each variable (statistically significant P.05); how-
ever, those reaching p-values less than 0.1 were included in a multivariate analysis. We ulti-
mately chose multiple linear regression by the enter method to generate the algorithm, given
the method would be more easily transformable into a useful equation in routine clinical prac-
tice. After this process, we selected those variables with p-values consistently below .05 to be
included in the pharmacogenetic algorithm. In the case of variables near significant with bio-
logical plausibility and previous evidence of association with acenocoumarol dosing, were also
included in the algorithm. The dependent variable was the acenocoumarol dosage required
(ln-transformed) to obtain a stable target INR range. As independent variables, we included
the selected demographic, clinical and genetic variables. To elucidate the contribution of the
patients´ demographic and clinical characteristics as currently used in clinical practice, a clini-
cal algorithm was designed including only those variables used in the pharmacogenetic
algorithm.
The performance of pharmacogenetic and clinical algorithms was evaluated by calculating
the coefficient of determination (R2) that represents the variability explained by each model.
The accuracy and precision of the model were assessed using the mean error (ME; mean of the
differences between the predicted and observed acenocoumarol dosages) and the mean abso-
lute error (MAE; mean absolute difference between the predicted and observed acenocoumarol
dosages). The ME and MAE were also calculated as the percentages of the observed acenocou-
marol dosage (%ME and %MAE). The ME reflects the accuracy of the prediction, and MAE is
an estimate of the model´s precision.
Clinical relevance
To evaluate the clinical relevance of the model, we classified the patients into 3 groups accord-
ing to the actual dosage administered: a low-dosage group (<11 mg/week), an intermediate-
dosage group (11–21 mg/week) and a high-dosage group (>21 mg/week). We calculated the
proportion of patients for whom the predicted dosage was within 20% of the actual dosage
(considered correctly dosed). We evaluated the predicted dosage by applying the pharmacoge-
netic and clinical algorithms.
All analyses were performed using SPSS 16.0 (IBM Inc., IL, USA).
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Results
Demographics
The generation cohort consisted of 556 patients; 283 of whom were women (50.9%); the mean
(SD) age was 68.7 (0.53) years. The validation cohort consisted of 129 patients, with a mean
age of 67.6 (1.3) years, 54 of whom were women (41.9%). There were missing data in both
groups: amiodarone use for 2 patients in the generation cohort and the weight and height in
1 patient in the validation cohort. Excluding the patients with missing data, 554 patients com-
prised the generation cohort, and 128 patients comprised the validation cohort. The clinical
and demographic features and genotype frequency of both groups are shown in Table 1. The
most common disease in our complete cohort was AF (47%) followed by TVD (29.5%). When
comparing the patients’ features between the various diseases (Table 2), we found that patients
with AF were older (72.44 ± 0.5 years) and had higher BMI (29.55 ± 0.27) (p< .001), and the
acenocoumarol dosage (13.49 ± 0.33 mg/week) was significantly lower than that of the other
groups (p< .001). Regarding the concomitant medication, this group included more patients
treated with amiodarone (9%) compared with the groups with other diseases (p< .001). There
were no differences in the genotype distribution between the various diseases.
Acenocoumarol dose algorithm
The clinical variables that were ultimately included in the algorithm were age (y), weight (kg),
amiodarone use, enzyme inducer status and INR target range (2–3 or 2.5–3.5). The genetic var-
iables that remained significant in the algorithm were CYP2C91/2, CYP2C91/3, CYP2C9
homozygous variants, VKORC1 heterozygous, VKORC1 homozygous variant and the CYP4F2
homozygous variant. The outcome was the natural logarithm of the mean weekly doses of ace-
nocoumarol (Table 3). We grouped the polymorphisms of the CYP2C9 homozygous variants
because their function appears to be similar. The APOE genotype was not included in the final
model because it did not reach statistical significance (p = .521, R2 = 0.1%).
Variability of the pharmacogenetic algorithm
The variability explained by the pharmacogenetic algorithm was 52.8% in the generation
cohort and increased to 64%, in the validation cohort, whereas the clinical algorithm explained
13.1% and 21.1% respectively. The accuracy of the pharmacogenetic algorithm in both cohorts
was good, with a low calculated ME (-0.11 mg for the generation cohort and 0.04 mg for the
validation cohort), whereas the accuracy for the clinical algorithm was higher: -1.55 (6.57) and
-1.62 (6.41), respectively. The precision calculated as MAE was good in the pharmacogenetic
algorithm: the MAE was 3.77 mg (3.48) in the generation cohort and 3.54 mg (2.99) in the vali-
dation cohort. For the clinical algorithm, the MAE was higher 4.99 (4.55) and 5.04 (4.25),
respectively. We also calculated the predicted dosage by both algorithms in the entire cohort.
For this cohort, the R2 was 15.1% for the clinical algorithm and 55% for the pharmacogenetic
algorithm. The ME and MAE were lower in the pharmacogenetic algorithm, which means that
the bias and precision were clearly better in this algorithm (Table 4).
The predictive performance of the pharmacogenetic algorithm was evaluated by disease. As
shown in Table 5, the patient group with the best prediction was the AF group, with an R2 of
57.4%, followed by the VR group, with an R2 of 56.3%.
Clinical Relevance
To test the clinical relevance of the algorithm, we calculated the percentage of patients correctly
classified within 20% of the actual dosage. The percentage of patients correctly classified by the
Acenocoumarol Pharmacogenetic Algorithm in a Mixed Spanish Population
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pharmacogenetic algorithm was 46%, whereas 34% were classified properly with the clinical
algorithm (Table 6).
If we classify the patients into the 3 dosage groups (<11 mg/week, 11–21 mg/week,>21
mg/week), we can see that the percentage of patients correctly classified is higher in the inter-
mediate group (11–21 mg/week) for both algorithms, whereas the difference between the 2
Table 1. Patients characteristics in the generation (n = 556) and validation (n = 129) cohorts.
Variables Generation cohort (n = 556) Validation cohort (n = 129) p
Sex, n (%)
Female/Male 283/273 (50.9/49.1) 54/75 (41.9/58.1) .078
Mean age, y (SD) 68.7 (12.41) 67.6 (14.80) .446
Mean weight, kg (SD) 75.8 (14.16) 78.06 (16.26)◆ .147
Mean height, m (SD) 1.62 (0.09) 1.64 (0.10)◆ .107
Mean body mass index, kg/m2 (SD) 28.73 (4.86) 28.93 (4.30)◆ .653
Underlying disease, n (%)
Thromboembolic venous disease 160 (28.8) 42 (32.6)
Auricular ﬁbrillation 263 (47.3) 59 (45.7)
Valve replacement 115 (20.8) 26 (20.2)
Other diseases 18 (3.2) 2 (1.6)
Mean acenocoumarol dosage, mg/week (SD) 15.16 (0.30) 15.5 (0.67) .632
Concurrent medications
Inductor drugs* [Yes/No], n (%) 107/448 (19.3/80.7)γ 29/100 (22.5/77.5) .412
Amiodarone [Yes/No], n (%) 27/527 (4.9/94.6)¥ 9/120 (7/93) .380
Phenotype, n (%)
11 mg/week 177 (31,8) 39 (30.2)
11–21 mg/week 279 (50.2) 62 (48.1)
21 mg/week 100 (18) 28 (21.7)
CYP2C9 genotype, n (%) .881
*1/*1 325 (58.5) 77 (59.7)
*1/*2 138 (24.8) 30 (23.3)
*1/*3 62 (11.2) 16(12.4)
*2/*2 12 (2.2) 2 (1.6)
*2/*3 14 (2.5) 4 (3.1)
*3/*3 5 (0.9) 0 (0)
VKORC1 genotype, n (%) .874
Homozygote wt/wt 202 (36.4) 47 (36.4)
Heterozygote 277 (49.8) 62 (48.1)
Homozygote mut/mut 77 (13.8) 20 (15.5)
CYP4F2 genotype, n (%)
MM 83 (14.6) 14 (12.3) .455
APOE rs7412 genotype, n (%) .621
Homozygote wt/wt 494 (88.9) 116 (89.9)
Heterozygote 58 (10.4) 13 (10.1)
Homozygote mut/mut 4 (0.7) 0 (0)
Abbreviations: SD, standard deviation; mut, mutated; wt, wild type.
* CYP inducers that were considered in this analysis included phenytoin, carbamazepine and rifampin
γ Missing data, n = 555
¥ Missing data, n = 554
◆ Missing data, n = 128
doi:10.1371/journal.pone.0150456.t001
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algorithms increases in the extreme-dosage groups. Thus, the pharmacogenetic algorithm cor-
rectly classified 32.4% of the low-dosage group, compared with 19.9% using the clinical algo-
rithm. Similarly, the pharmacogenetic algorithm correctly classified 41.4% of the high-dosage
group compared with only 6.3% with the clinical algorithm. Differences in the MAE were also
significant in the extreme-dosage groups between the 2 algorithms (Table 7).
Published pharmacogenetic algorithms for acenocoumarol show differences in the included
clinical/demographic and genetic variables. All account for over 40% of the variability in the
dosage of this drug. Table 8 shows the comparisons regarding the performance and included
variables between this new algorithm and others.
Discussion
Expensive new oral anticoagulants with a short history of clinical use are being marketed; how-
ever, coumarins such as warfarin, acenocoumarol and phenprocoumon are still the most
Table 2. Patients characteristics according to disease in the entire cohort.
Variables TVD (n = 202) AF (n = 322) VR (n = 141) OD (n = 20) p
Sex, n (%)
Men 100 (49.5) 176 (54.7) 63 (44.7) 9 (45) .218
Women 102 (50.5) 146 (45.3) 78 (55.3) 11 (55)
Mean age, y (SD) 66.12 (16.91) 72.44 (8.90)* 64.37 (10.32) 57.65 (15.83) < .001
Mean weight, kg (SD) 76.51 (16.20) 78.43 (13.44) ¥ 70.93 (13.84) 76.15 (10.84) < .001
Mean height, m (SD) 1.63 (0.091) 1.63 (0.091) ¥ 1.61 (0.10) 1.63 (0.083) .302
Mean body mass index, kg/m2 (SD) 28.67 (5.08) 29.55 (4.77) ¥ 27.15 (3.77) 28.81 (4.46) < .001
Median acenocoumarol dosage, mg/week (range) 15 (2.5–47) 13.49 (3.0–37)* 16.48 (2.0–38.5) 21 (10.0–61.5) < .001
Concurrent medications, n (%)
Enzyme inducers † 25 (12.5) 80 (24.8) 26 (18.4) 5 (25) .006
Amiodarone 2 (1) 29 (9)* ¥ 5 (3.5) 0 < .001
Phenotype, n (%) < .001
<11 mg/week 66 (32.7) 117 (36.3) 31 (22) 2 (10)
11–21 mg/week 86 (42.6) 169 (52.5) 75 (53.2) 11 (55)
>21 mg/week 50 (24.8) 36 (11.2) 35 (24.8) 7 (35)
CYP2C9 genotype, n (%) .084
Homozygote wt/wt 109 (54) 187 (58.1) 93 (66) 13 (65)
Heterozygote 84 (41.58) 112 (34.8) 45 (31.9) 5 (25)
Homozygote mut/mut 33 (16.3) 43 (13.4) 19 (13.5) 2 (10)
CYP4F2 genotype, n (%)
MM 26 (12.9) 53 (16.5) 16 (11.3) 2 (10) .411
APOE rs7412 genotype, n (%) .311
Homozygote wt/wt 176 (87.13) 292 (90.7) 127 (90.1) 15 (75)
Heterozygote 24 (11.9) 29 (9) 13 (9.2) 5 (25)
Homozygote mut/mut 2 (1) 1 (0.3) 1 (0.7) 0
Abbreviations: AF, atrial ﬁbrillation; OD, other diseases; SD; standard deviation; VR, valve replacement; TVD, thromboembolism venous disease; mut,
mutated; wt, wild type.
† CYP inducers that were considered in this analysis included phenytoin, carbamazepine and rifampin
* Group with signiﬁcant differences compared with other groups
¶ Missing data, n = 201
¥ Missing data, n = 321
doi:10.1371/journal.pone.0150456.t002
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frequently prescribed drugs for the management of TVD, AF and VR. The high interindividual
variability in the dosage requirements of coumarins has been attributed to several clinical and
demographic factors and genetic variations. This high variability markedly affects the time
Table 3. Pharmacogenetic and clinical algorithms.
Pharmacogenetic algorithm
Beta Variable P-value Adj R2 (%) Cumulative R2 (%)
3.181 Intercept
-0.010 Age < .001
0.005 Weight < .001
0.070 Enzyme inducer status .053
-0.337 Amiodarone status < .001
0.086 INR target range .014
Clinical variables 13.1 13.1
-0.111 CYP2C9 *1/*2 < .001
-0.323 CYP2C9 *1/*3 < .0001
-0.691 CYP2C9 *2/*2 or *2/*3 or *3/*3 < .0001
CYP2C9 14.3 27.4
-0.302 VKORC1 A/G < .001
-0.727 VKORC1 A/A < .001
VKORC1 22.9 50.3
0.214 CYP4F2 MM < .001
CYP4F2 2.5 52.8
Clinical Algorithm
2.951 Intercept
-0.011 Age < .001
0.004 Weight .013
0.045 Enzyme inducer status .357
-0.290 Amiodarone status < .001
0.086 INR target range .014
Clinical variables 13.1 13.1
Beta: standardized regression coefﬁcient
The pharmacogenetic algorithm: natural logarithm of the mean weekly doses of acenocoumarol = 3.181–0.010*age (y) + 0.005*weight (kg) + 0.070 (if
enzyme inducer is used)– 0.337 (if amiodarone is used)– 0.111 (if CYP2C9*1/*2)– 0.323 (if CYP2C9*1/*3)– 0.691 (if CYP2C9 homozygote mutated)–
0.302 (if VKORC1 A/G)– 0.727 (if VKORC1 A/A) + 0.214 (if CYP4F2 MM) + 0.086 (if INR target is 2.5–3.5). The outcome is the natural logarithm of the
mean acenocoumarol dosage in mg/week.
doi:10.1371/journal.pone.0150456.t003
Table 4. Predictive performance of the pharmacogenetic and clinical algorithms in the generation, validation and entire cohorts.
Pharmacogenetic Algorithm Clinical Algorithm
Generation Cohort Validation Cohort Entire Cohort Generation Cohort Validation Cohort Entire Cohort
R2 52.8% 64% 55% 13.1% 21.1% 15.1%
ME -0.11 (3.48) 0.04 (4.65) -0.09 (5.04) -1.55 (6.57) -1.62 (6.41) -1.56 (6.54)
MAE 3.77 (3.48) 3.54 (2.99) 3.73 (3.39) 4.99 (4.55) 5.04 (4.25) 4.99 (4.49)
%ME 10.15 (38.17) 9.95 (35.85) 10.12 (37.72) 9.62 (62.76) 8.95 (54.9) 9.49 (61.32)
%MAE 28.52 (27.3) 26.64 (25.89) 28.17 (27.03) 38.97 (50.1) 38.21 (40.29) 38.83 (48.38)
Abbreviations: ME: mean error (predicted–observed); %ME: mean error expressed as a percentage (%ME = ME/Observed*100); MAE: mean absolute
error (= SQR[(Predicted-Observed)2]); %MAE: mean absolute error expressed as a percentage (%MAE = MAE/Observed*100).
doi:10.1371/journal.pone.0150456.t004
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within the target INR and the clinical outcomes. Jones et al. showed that a 10% increase in the
time out of range was associated with a 29% higher risk of mortality, a 10% increase in the risk
of ischemic stroke and a 12% increase in all thromboembolic events [27].
For patients with TVD, the risk of progression, recurrence and death due to PE is greatest in
the first weeks after the diagnosis. Despite modern diagnostic and treatment methods, PE con-
tinues to have a high mortality rate during the first 3 months, which is probably due to the
recurrence of embolism. The frequency of PE could be lowered if more intensive anticoagula-
tion were used [28].
For patients with AF, preventing stroke and thromboembolism are the primary therapeutic
goals. For these patients, the expected embolic event rate increases from 2.5% to over 12% per
year if they are not properly anticoagulated [29]. Rates of major hemorrhage reported for
patients with AF undergoing warfarin treatment range from 1.3 to 7.2 per 100 person-years.
Patients with AF tend to be older, have associated comorbidities and take more concomitant
medications [29]. The first 90 days are associated with a 3-fold increased risk of major hemor-
rhage, which is associated with the advanced age of these patients [30]. These data correspond
with those of our study; in which patients with AF had the lowest average dose of acenocou-
marol, which could increase the likelihood that some patients receive a higher dose of aceno-
coumarol at the beginning of the treatment. In clinical practice, the estimation of both bleeding
and stroke risks are recommended to guide decisions on thromboprophylaxis therapy [31,32].
This study confirms that acenocoumarol algorithms can explain more than 50% of the
interindividual variability in the most appropriate dosage of acenocoumarol for stable anticoa-
gulation. The algorithm previously designed and validated by our group was developed for a
patient cohort with TVD [23]. Given the fact that these patients are typically younger, have less
comorbidity and take fewer concomitant medications, we believe this algorithm might not be
useful for other diseases that require anticoagulation with acenocoumarol due to the differ-
ences (mainly demographic and clinical) between patients with TVD and those with other
Table 5. Predictive performance of the pharmacogenetic algorithm by disease in the entire cohort (n = 682).
TVD (n = 202) AF (n = 322) VR (n = 141) OD (n = 20)
R2 51.5% 57.4% 56.3% 45.2%
ME -1.12 (5.53) 0.59 (4.07) 0.22 (5.16) -2.59 (9.43)
MAE 4.12 (3.85) 3.28 (2.47) 3.91 (3.36) 5.81 (7.78)
%ME 2.11 (37.19) 15.23 (38.07) 11.47 (36.52) -1.19 (31.80)
%MAE 26.55 (26.06) 29.68 (28.26) 27.32 (26.73) 26.13 (17.15)
Abbreviations: AF, atrial ﬁbrillation; OD, other diseases; VR, valve replacement; TVD, thromboembolism venous; ME: mean error (predicted–observed); %
ME: mean error expressed as a percentage (%ME = ME/Observed*100); MAE: mean absolute error (= SQR[(Predicted-Observed)2]); %MAE: mean
absolute error expressed as a percentage (%MAE = MAE/Observed*100).
doi:10.1371/journal.pone.0150456.t005
Table 6. Patients correctly classified (predicted dose within ± 20% of the actual dosage) by genetic and clinical algorithms in the generation, vali-
dation and entire cohorts (n = 682).
% Correctly classiﬁed
Pharmacogenetic algorithm Clinical algorithm p-value
Generation cohort (n = 554) 46.9% 34.7% < .001
Validation cohort (n = 128) 46.5% 34.1% < .001
Entire cohort (n = 685) 46.9% 34.5% < .001
doi:10.1371/journal.pone.0150456.t006
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diagnoses. Nevertheless, Jimenez-Varo et al., in a recently published study, reported that imple-
mentation of the algorithm previously designed by our group led to the highest percentage of
correctly classified patients (40.7%) compared with the other algorithms published to date for
acenocoumarol [33].
The algorithm described here leads to similar results as those from other algorithms [22,24] per-
formed for the European population regarding the factors influencing stable dosages of coumarins.
The most important factors for dosage prediction are theVKORC1 and CYP2C9 genotypes,
whereas CYP4F2 has less influence. Regarding clinical variables, age and weight were the most
important clinical factors for dosage prediction. Other variables we found significant, such as con-
comitant medications and target INR, are not consistently included in published algorithms.
When considering the entire cohort, this algorithm explained 55% of the interindividual
variability of the most appropriate acenocoumarol dosage; clinical variables explained only
15.1% of this variability. The results show that the inclusion of genetic variables greatly
increases the predictability of the dosage required for each patient. Algorithms published for
other populations would not be comparable with the results of this algorithm. There are varia-
tions in the frequency of polymorphisms among various ethnic groups; some genes have more
impact on one ethnic group than another. Thus, in the study performed on the Northern
Indian population [20], VKORC1 and CYP4F2 polymorphisms were the principal genetic vari-
ables, whereas in the algorithm developed for Southern Indians and those for the European
population, VKORC1 and CYP2C9 are the genetic factors that contribute most to the perfor-
mance of these algorithms. Furthermore, our algorithm differs from those published for the
Indian population [20,21]; the authors of that algorithms included GGCX gene polymorphisms
(rs11676382), which we do not.
When the predictive performance of the pharmacogenetic algorithm was evaluated by dis-
ease, the best prediction was for the AF group (R2 of 57.4%), which was similar to the R2 found
for the VR group. For the patients with TVD, the variability explained for the algorithm was
somewhat lower (R2 = 51.5%). However, the MAE and %MAE were similar in all groups, con-
firming that the algorithm worked similarly for all groups.
Not surprisingly, when using standard starting dosages or dosages based on clinical vari-
ables, most of the incorrectly dosed patients were those who needed low or high
Table 7. Patients correctly classified (predicted dose within ± 20% of actual dosage) and MAE from the entire cohort (n = 682) by genetic and clini-
cal algorithms according to dosage groups.
Dosage Group Pharmacogenetic algorithm Clinical Algorithm Difference p-value*
Low (11 mg/week)
% correctly classiﬁed 32.4% 19.9% 12.5% < .001
Mean MAE (SD) 3.12 (2.32) 4.37 (2.78) 1.25 (3.01) < .001
95% CI 0.85 to 1.66
Median (11–21 mg/week)
% correctly classiﬁed 58.1% 54.5% 3.6% .118
Mean MAE (SD) 3.01 (2.32) 3.15 (2.36) 0.14 (2.97) .403
95% CI 0.18 to 0.45
High (21 mg/week)
% correctly classiﬁed 41.4% 6.3% 34.8% < .001
Mean MAE (SD) 6.64 (5.26) 10.92 (5.93) 4.28 (3.76) < .001
95% CI 3.62 to 4.93
Abbreviations: CI, conﬁdence interval; MAE, mean absolute error (= SQR[(predicted-observed)2]); SD, standard deviation.
doi:10.1371/journal.pone.0150456.t007
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acenocoumarol dosages. These are the patients we can expect to benefit most from the pharma-
cogenetic algorithm. In this study, the percentage of patients for whom the pharmacogenetic
algorithm would have improved acenocoumarol dosing when compared with a clinical algo-
rithm would have been approximately 12.7% (87 patients out a total of 685). Most were
patients needing low dosages (27 patients) and notably higher dosages (45 patients). The for-
mer would have been overdosed for a number of weeks (until clinical dose adjustments reached
a stable INR) and could have been at risk of bleeding, whereas the latter could have been under-
dosed and would have been at risk of thromboembolic events.
There were differences between the 2 algorithms published by our group regarding the variables
included. On one hand, we included the target INR variable in this new algorithm, as justified by
the different target INRs for the various diagnoses. We found that the target INR had a modest but
significant influence (see Table 3). On the other hand, the contribution of APOE to the total vari-
ability was not confirmed in this study because it was not significant (p = 0.521, R2 = 0.1%), and
was therefore not included in the algorithm. The inclusion in the algorithm of the taking of certain
drugs such as enzyme inducers and amiodarone, is also justified by data in the literature on their
influence on the coumarin dose and, as we have seen in the model, their influence is significant
(beta of 0.070 and -0.337 respectively). Amiodarone intake was one of the variables included in the
algorithm published by the EU-PACT group, with a similar result (beta of -0.377).
The usefulness of pharmacogenetic algorithms in a clinical setting has been tested in 3 pub-
lished clinical trials, 2 of which were performed with warfarin and 1 with acenocumarol and
phenprocoumon. In 2013, a randomized trial of genotype-guided acenocoumarol dosing
showed that the pharmacogenetic algorithm, which included clinical and genetic variables, did
not improve the percentage of time in the therapeutic INR range during the 12 weeks after the
start of therapy compared with the clinical algorithm [34]. The EU-PACT group, however,
reported that pharmacogenetics-based warfarin dosing was better than standard dosing, with a
higher percentage of time in the therapeutic INR range than traditional clinical dosages during
the start of warfarin therapy [35]. The results of these studies are controversial in terms of the
applicability of pharmacogenetic algorithms, and certainly there are variables that are not
included in these algorithms, which in the context of clinical trials cannot be controlled.
Pharmacogenetic algorithms have typically been developed by collecting information from
individuals with various demographic, clinical and genetic characteristics. Both clinical and phar-
macogenetic algorithms show similar accuracy in predicting the dose of wild-type genotype
patients; however, algorithms that integrate genetic information are more accurate and useful for
patients with allelic variants because these patients often have extreme dosages of acenocoumarol,
for whom INR stabilization becomes more difficult and time-consuming to achieve.
There are a number of limitations in this study. A number of parameters that have also been
linked to changes in the required stable coumarins dosages were not included, such as smoking
status, other concomitant medications and the dietary vitamin K intake. All are important fac-
tors to keep in mind when establishing a stabilized dosage of acenocoumarol.
In conclusion, our new algorithm can provide better prediction, when compared with the
clinical algorithm, of the ideal acenocoumarol dosage for a broad spectrum of patients who are
starting treatment with this drug, particularly those who need extreme dosages. The perfor-
mance of the pharmacogenetic algorithm is similar for patients with different diseases despite
the demographic and clinical variations among the patients.
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